Centrally acting agents and visceral sensitivity

Fioramonti, Jean; Buéno, Lionel

doi:10.1136/gut.51.suppl_1.i91

Cited by 30 publications

(22 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trimebutine and fedotozine have shown a degree of efficacy in the treatment of IBS [4,19,20]. Other opiates have also been found to alleviate pain, some through peripheral activity.…”

Section: Discussionmentioning

confidence: 96%

“…The diary was based on a validated questionnaire by Francis et al [12] but modified by a motility-specialized gastroenterologist team. Investigated parameters were (a) overall abdominal pain (none [0], mild [1], moderate [2], or severe [3]); (b) bowel urgency (complete control [1], satisfactory control [2], or lack of control [3]); (c) stool consistency (hard [1], firm [2], soft [3], or liquid [4]); and (d) number of stools passed. A global assessment evaluation was undertaken by a weekly assessment of the overall adequacy of treatment in relieving bowel symptoms as opposed to baseline and scored as poor (0), fair (1), good (2), very good (3), or excellent (4).…”

Section: Study Variablesmentioning

confidence: 99%

“…Opioid agents have a marked effect on gut motility and secretion and can alleviate visceral pain [4]. An in vitro study in a mouse dorsal root ganglion (DRG) model demonstrated dual modulation of action potential duration.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Low-Dose Naltreoxone for the Treatment of Irritable Bowel Syndrome: A Pilot Study

et al. 2006

View full text Add to dashboard Cite

Preclinical studies have shown that a very low dose of naltreoxone hydrochloride (NTX), an opiate antagonist, can block excitatory opioid receptors without affecting inhibitory opioid receptors, resulting in analgesic potency without side effects. The present study assessed the efficacy and safety of PTI-901 (low-dose NTX) treatment in Irritable bowel syndrome (IBS) patients. Forty-two IBS patients participated in an open-label study. Participants received 0.5 mg PTI-901/day for 4 weeks and were evaluated during baseline, during treatment, and at 4-week follow-up. Patients recorded degree of abdominal pain, stool urgency, consistency, and frequency. Primary outcomes were number of pain-free days and overall symptom relief, evaluated by a global assessment score. Data were analyzed per protocol. Global assessment improved in 76% of 42 patients. During treatment, the mean weekly number of pain-free days increased from 0.5+/-1 to 1.25+/-2.14 (P=0.011). There were no significant adverse reactions. PTI-901 improves pain and overall feeling, and is well tolerated by IBS patients. A large, randomized, double-blind, placebo-controlled study is justified.

show abstract

“…Trimebutine and fedotozine have shown a degree of efficacy in the treatment of IBS [4,19,20]. Other opiates have also been found to alleviate pain, some through peripheral activity.…”

Section: Discussionmentioning

confidence: 96%

Section: Study Variablesmentioning

confidence: 99%

See 1 more Smart Citation

Low-Dose Naltreoxone for the Treatment of Irritable Bowel Syndrome: A Pilot Study

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Various clinical studies have demonstrated that TMB is an effective treatment for abdominal pain, gastroesophageal reflux (Kountouras et al, 2002) and altered bowel habit in IBS patient (Delvaux and Wingate, 1997;Poynard et al, 2001;Fioramonti and Bueno, 2002). In association with ruscogenines, TMB is able to reduce hemorrhoidal pain and to improve anal damage (Evreux, 1989).…”

Section: Introductionmentioning

confidence: 95%

Beneficial effect of trimebutine and N-monodesmethyl trimebutine on trinitrobenzene sulfonic acid-induced colitis in rats

et al. 2004

View full text Add to dashboard Cite

“…Trimebutine has been commonly used for the treatment of IBS to relieve abdominal pain and alter bowel habits, although its clinical efficacy and mechanism of action remain still unclear (Delvaux and Wingate, 1997;Fioramonti and Bueno, 2002). This drug is known to have a unique spasmolytic activity, which might be related to its local anesthetic, antimuscarinic, and weak mu opioid agonist effects (Roman et al, 1999).…”

mentioning

confidence: 98%

Trimebutine as a modulator of gastrointestinal motility

Lee

Kim

2011

Arch. Pharm. Res.

View full text Add to dashboard Cite

Trimebutine has been used for treatment of both hypermotility and hypomotility disorders of the gastrointestinal (GI) tract, such as irritable bowel syndrome. In this issue, Tan et al. (2011) examined the concentration-dependent dual effects of trimebutine on colonic motility in guinea pig. The authors suggested that trimebutine attenuated colonic motility mainly through the inhibition of L-type Ca(2+) channels at higher concentrations, whereas, at lower concentrations, it depolarized membrane potentials by reducing BK(ca) currents, resulting in the enhancement of the muscle contractions. Trimebutine might be a plausible modulator of GI motility, which gives an insight in developing new prokinetic agents. Further studies to elucidate the effects of trimebutine on the interstitial cells of Cajal, the pacemaker in GI muscles would promote the therapeutic benefits as a GI modulator.

show abstract

Centrally acting agents and visceral sensitivity

Cited by 30 publications

References 67 publications

Low-Dose Naltreoxone for the Treatment of Irritable Bowel Syndrome: A Pilot Study

Low-Dose Naltreoxone for the Treatment of Irritable Bowel Syndrome: A Pilot Study

Beneficial effect of trimebutine and N-monodesmethyl trimebutine on trinitrobenzene sulfonic acid-induced colitis in rats

Trimebutine as a modulator of gastrointestinal motility

Contact Info

Product

Resources

About